AstraZeneca Says Durvalumab Less Likely To Get Early Approval
This article was originally published in The Pink Sheet Daily
Executive Summary
Approvals for front-runners Keytruda and Opdivo have forced the UK pharma to concede there is a lower likelihood its ATLANTIC lung cancer trial can be used for early US approval in NSCLC for durvalumab.